Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies.

The use of serotonergic psychedelics has gained increasing attention in research, clinical practice and society. Growing evidence suggests fast-acting, transdiagnostic health benefits of these 5-hydroxytryptamine 2A receptor agonists. Here, we provide a brief overview of their benefits for psychological, cardiovascular, metabolic, neurodegenerative, and immunological pathologies. We then review their effect on mitochondria including mitochondrial biogenesis, functioning and transport. Mitochondrial dysregulation is a transdiagnostic mechanism that contributes to the aforementioned pathologies. Hence, we postulate that psychedelic-induced effects on mitochondria partially underlie their transdiagnostic benefits. Based on this assumption, we propose new treatment indications for psychedelics and that the health benefits induced by psychedelics depend on patient-specific mitochondrial dysregulation.

Citation

Patrick Fissler, Anja Vandersmissen, Marco Filippi, Rezan Nehir Mavioglu, Felix Scholkmann, Alexander Karabatsiakis, Rainer Krähenmann. Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies. Journal of psychopharmacology (Oxford, England). 2023 Jul;37(7):679-686

Mesh Tags

Substances

PMID: 37122193

search → result